Galectin Therapeutics (GALT) reported a net loss of $9.1 million, or $0.14 per basic and diluted share, for the three months ended June 30, 2026. Net loss applicable to common stockholders was $9.2 million, compared with $7.6 million in the prior-year quarter.
The company said it reached agreement with the FDA on key elements of its planned Phase 3 belapectin trial in MASH cirrhosis and portal hypertension. Galectin anticipates submitting the registrational protocol in the third quarter of 2026.
- Cash and cash equivalents totaled $13.2 million at June 30, 2026.
- Research and development expense was $2.1 million, down from $3.3 million a year earlier.
- General and administrative expense was $1.8 million, up from $1.4 million.
- Chairman Richard E. Uihlein converted approximately $105.8 million of debt and accrued interest into common stock effective July 31, 2026.
- The conversion resulted in the issuance of 34,376,167 common shares.
$GALT Insider Trading Activity
$GALT insiders have traded $GALT stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $GALT stock by insiders over the last 6 months:
- KHURRAM JAMIL (Chief Medical Officer) has made 0 purchases and 6 sales selling 76,412 shares for an estimated $370,858.
- HAROLD H. SHLEVIN has made 0 purchases and 2 sales selling 30,000 shares for an estimated $150,890.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$GALT Hedge Fund Activity
We have seen 51 institutional investors add shares of $GALT stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,189,116 shares (+273.9%) to their portfolio in Q2 2026, for an estimated $10,157,498
- GEODE CAPITAL MANAGEMENT, LLC added 695,608 shares (+113.5%) to their portfolio in Q2 2026, for an estimated $3,227,621
- MILLENNIUM MANAGEMENT LLC added 562,926 shares (+239.0%) to their portfolio in Q1 2026, for an estimated $1,570,563
- TWO SIGMA INVESTMENTS, LP added 450,451 shares (+2711.6%) to their portfolio in Q1 2026, for an estimated $1,256,758
- MARSHALL WACE, LLP removed 388,902 shares (-31.9%) from their portfolio in Q2 2026, for an estimated $1,804,505
- STATE STREET CORP added 309,347 shares (+119.7%) to their portfolio in Q2 2026, for an estimated $1,435,370
- CITADEL ADVISORS LLC added 290,360 shares (+inf%) to their portfolio in Q1 2026, for an estimated $810,104
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
